This disease is usually aggressive with high frequency of transformation

to mast cell leukemia (71). Treatment Treatment for GI lymphomas primarily depends on the grade and stage at presentation and association with H. pylori infection. For instance, low-grade, stage I MALT lymphoma associated with H. pylori follows a conservative approach with triple antibiotics to eradicate the microorganism. This process has been repeatedly documented in producing excellent clinical outcome with approximately 75-80% remission rate; thus, #PRT062607 solubility dmso keyword# it has been considered the primary mode of treatment in stage I, H. pylori-associated cases (4-6,35-38,40). Chemotherapy with or without radiation therapy is reserved Inhibitors,research,lifescience,medical for more advanced diseases or in H. pylori-associated primary GI lymphomas which are resistant to antibiotics, and also in cases without H. pylori association (37-39). Surgery is rarely performed and is only pursued in cases with severe complications (40) such as obstruction and perforation, or in localized disease with prior resistance to neoadjuvant chemotherapy. Conclusions Primary lymphomas of the GI tract may consist of mature B, T or NK/T cell neoplasms, of which, the two most commonly encountered

morphologic subtypes are extranodal MALT lymphoma and DLBCL (1). The stomach is the most frequent site involved (2). Moreover, association of primary Inhibitors,research,lifescience,medical GI lymphomas with H. pylori infection, particularly observed in extranodal MALT lymphoma and in a few cases of DLBCL has revolutionized treatment approach, with conservative antibiotic regimen as the primary therapeutic method in low-grade, stage I diseases (4-6,35-38). On the other hand, T cell and NK/T cell GI tract Inhibitors,research,lifescience,medical lymphomas often entail a more aggressive clinical behavior (8,9,57,58,61-63). However, cases of benign, indolent NK-cell enteropathy or lymphomatoid gastropathy have been described recently Inhibitors,research,lifescience,medical (10,11), and thus, it is imperative

to distinguish this entity from true NK/T cell neoplasm in order to initiate proper clinical management. Acknowledgments The authors would like to thank Dr. Jeffrey D. Cao for sharing GI lymphoma cases from the Loma Linda Veterans Hospital, and Dr. Craig Zuppan for his help and instructions in photomicrograph editing. Disclosure: (-)-p-Bromotetramisole Oxalate The authors declare no confict of interest.
In the current issue of Journal of Gastrointestinal Oncology, Ballehaninna and Chamberlain (1) provide a comprehensive appraisal of the utility of Ca19-9 in pancreatic cancer. The authors suggest a number of roles for Ca19-9 including: (I) As a diagnostic and screening tool in symptomatic patients; (II) In the assessment of tumour stage and respectability; (III) As a biomarker of prognosis following resection; (IV) In the assessment of response to chemotherapy; (V)As a predictor of post-operative recurrence. Indeed, the only area where Ca19-9 would not appear to be useful is in population screening.